Ondansetron has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


ondansetron studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
GTH001/94 IV An evaluator-blind, randomised, within-patient comparison of ondansetron given three times daily vs. twice daily with or without dexamathasone vs. metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting in children.
S3A 40022 or ZOF-SLT-Päd IV Open-label multicentre-study to evaluate efficacy and tolerability of a novel fast-dissolving formulation of ondansetron to prevent nausea and vomiting after therapy with non-platinum-containing chemotherapy in paediatric patients.
S3A 40068 (ZOF-POND-LO2) IV Randomised, double-blind, placebo-controlled, multicentre, parallel group study to evaluate the efficacy and safety of a Zofran iv in the prevention of PONV in major gynaecological surgery.
S3A 40069 or ZOF-POND-LO3 IV Randomised single centre double-blind study to compare the efficacy and safety of a single iv dose of Zofran administered either prior to induction or prior to cessation of anaesthesia in the prevention of PONV in patients having general anaesthesia and undergoing major surgery.
S3A40095 (517/110) IV An assessment of the effect of schedule and maintenance on the antiemetic efficacy and safety of ondansetron combined with dexamethasone as acute and maintenance therapy in patients receiving moderately emetogenic chemotherapy.
S3A40319 IV A Phase IV, Multi-Center, Two-Arm, Single-Dose Pharmacokinetic Study of Intravenous ZOFRAN in Pediatric Surgical Patients from 1 Month to 24 Months of Age
S3A-408 IV An Open-Label Study of IV Ondansetron Plus Dexamethasone for the Prevention of Emesis Associated with Different Degrees of Emetogenic Chemotherapy
S3A-409 IV A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron Versus Droperidol for the Prevention of Postoperative Nausea and Vomiting in Outpatient Surgery
S3A-410 IV A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron Versus Droperidol for the Prevention of Postoperative Nausea and Vomiting in Outpatient Surgery.
S3AA4001 IV A Multicenter Study to Evaluate the Efficacy and Safety of a Repeat Dose of Ondansetron in Ambulatory Surgery Patients who do not Achieve Adequate Control of Postoperative Nausea and Vomiting Following Prophylaxis With Open-Label Intravenous Ondansetron
S3AA4002 IV A Randomized, Double-Blind Comparison of Single-Dose Intravenous Ondansetron Versus Single-Dose Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin Chemotherapy
S3AA4003/S3AA4011 IV A Stratified, Randomized, Double-Blind Comparison of Oral Ondansetron and Compazine® Spansules® in the Prevention of Nausea and Vomiting Associated With Moderately-Emetogenic Chemotherapy
S3AM48 IV A Multicentre, Double-Blind, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Oral Ondansetron 8mg BD and 16mg OD in the Control of Nausea and Emesis Induced by Cyclophosphamide Containing Chemotherapy in Breast Cancer Patients
S3AM49 IV A Multicentre, Double-Blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Oral Ondansetron 8mg BD and 16mg OD in the Control of Nausea and Emesis Induced by Cyclophosphamide Containing Chemotherapy in Cancer Patients
S3AM51 IV A Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Safety of Ondansetron plus Dexamethasone, Ondansetron and Tropisetron in the Control of Acute Cisplatin-induced Nausea and Emesis
S3AM52 IV A randomised, double-blind, parallel group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
S3AP47 IV A Pilot Study to Determine the Optimal Dose, Tolerance and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Maintenance Therapy Used in Children with Acute Lymphoblastic Leukaemia
S3GT11 IV A randomised double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of a single intravenous dose of Ondansetron in the prevention of post-operative nausea and emesis in paediatric patients having general anaesthesia and undergoing surgery for tonsillectomy with or without adenoidectomy
ZOF-011/2002 IV Open label treatment observational cohort (TOC) of a Single Dose Therapy with Zofran for the Prevention and Therapy of Chemotherapy-induced Nausea and Emesis (CINV)
ZOF100401 IV A Multicenter, Randomized, Double Blind, Placebo-Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Intravenous Ondansetron Hydrochloride with Intravenous Dexamethasone Versus Intravenous Ondansetron Hydrochloride for the Prevention of Post-Operative Nausea and Vomiting in Female Subjects Undergoing Outpatient Laparoscopic Surgeries Associated with a High Emetogenic Risk.
ZOF100419 IV A Randomized, Double Blind, Active-Controlled Multicenter Clinical Trial To Evaluate The Anti-Emetic Prophylactic Efficacy Of Ondansetron On Post-Operative Nausea And Vomiting In Patients With Intravenous Patient Controlled Analgesia
ZOF-EG-16 IV A single blind, placebo-controlled, multicentre study of intravenous ondansetron in the prevention of post-operative emesis (retching and vomiting) in paediatric patients undergoing strabismus surgery.
GL/PNV/001 III A randomised, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety profile of a single 4mg intravenous bolus dose of ondansetron in the prevention of post-operative nausea and emesis in patients having general anaesthesia and undergoing major gynaecological surgery.
GTH001/92 III Comparison of ondansetron and placebo for preventing postoperative nausea and emesis in gastrointestinal tract surgery: a multicenter randomised controlled trial.
OND A 01 90 (S3AM23) III A Multicentre Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR 38032F) Administered Either as a Single Intravenous Dose or a Continuous Infusion in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-containing Cancer Chemotherapy Regimens
ONDA0801 III Oral Ondansetron Regimen vs Alizapride Injection and Tablet Regimen in the Prophylaxis of Emesis Induced by Chemotherapy in Breast Cancer
S3A-245 III Treatment of Postoperative Nausea and Vomiting: A Randomized Double-Blind Study of Intravenous Ondansetron in Patients Undergoing Surgical Procedures on an Outpatient Basis
S3A-248 III Prevention of Postoperative Nausea and Vomiting: A Randomized Double-Blind Study of Intravenous Ondansetron in Female Patients Undergoing Surgical Procedures on an Ambulatory Basis
S3A-249 III A Randomized, Double-Blind, Placebo-Controlled, Study of the Effects of Intravenous Ondansetron on Atracurium-Induced Neuromuscular Blockade in Patients Undergoing Surgical Procedures
S3A30065 III Risk-adapted management of postoperative nausea and postoperative vomiting: a phase III-study to assess safety and efficacy of intravenous ondansetron and oral disintegrating tablets of ondansetron.
S3A30067 III Ondansetron plus Placebo versus Ondansetron plus Dexamethasone under consideration of a risk score for the prophylaxis of post operative nausea and vomiting (PONV)
S3A-311 III A Randomised, Double-Blind Comparison of Ondansetron Suppository and Oral Ondansetron in the Prevention of Emesis and Nausea Associated with Cyclophosphamide Chemotherapy
S3A-351 III A Single-Blind Evaluation of Intravenous GR-C507/75 Compared to Intravenous Metoclopramide in the Prevention of Nausea and Vomiting Associated With High-Dose Cisplatin
S3A-352 III A Randomized Double-Blind Comparison of Three Dose Levels of Intravenous GR-C507/75 (GR 38032F) in the Prevention of Nausea and Vomiting Associated with Cisplatin
S3A-354 III A Double-Blind Comparison of Intravenous GR-C507/75 (GR38032F) and Placebo in the Prevention of Nausea and Vomiting Associated With Cisplatin or Cyclophosphamide Chemotherapy
S3A-356 III A Double-Blind Evaluation of Three Different Doses of Intravenous GR-C507/75 (Ondansetron) in the Prevention of Nausea and Vomiting Associated With a Multiple Day Regimen of Cisplatin
S3A-359 III A Randomized Double-Blind Comparison of Three Dose Levels of Intravenous GR-C507/75 in the Prevention of Nausea and Vomiting Associated With Cisplatin
S3A-361 III A Randomized, Double-Blind, Placebo-Controlled Dose Range Evaluation of Oral GR 38032F in the Prevention of Nausea and Vomiting Associated With Non-Cisplatin Chemotherapy
S3A-362 III A Randomized, Double-Blind, Placebo-Controlled Dose Range Evaluation of Oral GR 38032F in the Prevention of Nausea and Vomiting Associated With Non-Cisplatin Chemotherapy
S3A-363 III A Randomized, Double-Blind Comparison of Oral Ondansetron and Compazine® Spansules® in the Prevention of Nausea and Vomiting Associated With Non-Cisplatin Chemotherapy
S3A-366 III A Stratified, Randomized, Double-Blind Comparison of Intravenous Ondansetron Administered as a Multiple Dose Regimen Versus Two Single Dose Regimens in the Prevention of Cisplatin-Induced Nausea and Vomiting
S3A-372 III A Double-Blind, Placebo-Controlled Study of Oral Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Female Patients
S3A-375 III A Randomized, Double-Blind, Placebo-Controlled Evaluation of Oral Ondansetron Administered Twice Daily in the Prevention of Nausea and Vomiting Associated with Non-Cisplatin Chemotherapy
S3A-376 III A Stratified, Randomized, Double-Blind, Comparison of Oral Ondansetron Administered Twice Daily Versus Three Times Daily in the Prevention of Nausea and Vomiting Associated with Non-Cisplatin Chemotherapy
S3A-379 III Prevention of Postoperative Nausea and Vomiting: A Randomized, Stratified, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Male Subjects Undergoing Surgical Procedures on an Ambulatory Basis.
S3A-380 III A randomized, double-blind, placebo-controlled, multi-center study of intravenous ondansetron for the prevention of postoperative emesis in pediatric patients undergoing outpatient surgery.
S3A-381 III A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Intravenous Ondansetron for the Treatment of Postoperative Emesis in Pediatric Patients Undergoing Outpatient Surgery
S3A40323 III A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Intravenous Ondansetron Hydrochloride 0.1 mg/kg for the Prevention of Postoperative Emesis in Pediatric Surgical Subjects Ages 1 Month to 24 Months Who Are Undergoing Routine Surgery Under General Anesthesia.
S3AA3004/3007 III A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated With Moderately-High Emetogenic Chemotherapy
S3AA3012 III A Randomized, Double-Blind Study of Oral Ondansetron, 8mg Twice Daily, 24mg Once Daily and 32mg Once Daily, in the Prevention of Nausea and Vomiting Associated With Cisplatin Chemotherapy
S3AA3013 III A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Single Dose Ondansetron 8mg and Single Dose Ondansetron 16mg for the Treatment of Opioid-Induced Nausea and Emesis in Subjects Experiencing Acute Pain
S3AB3003 III A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Compare the Efficacy and Safety of Intravenous Doses of Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis in Patients Undergoing Elective Major Abdominal Surgery
S3AB3004 III A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Intravenous Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis In-Patients Undergoing Major Gynaecological Surgery
S3AB3005 III A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study to Compare the Efficacy and Safety of Ondansetron 8mg bd Tablet and Ondansetron ZYDIS™ 8mg bd in the Control of Emesis and Nausea Induced by Cyclophosphamide-Containing Chemotherapy Treatment in Cancer Patients
S3AB3006 III A multicentre, double-blind, randomised, parallel group study to compare the efficacy and safety of two ondansetron regimens in the control of emesis and nausea induced by cancer chemotherapy in paediatric patients.
S3AB3008 III A multicentre, double-blind, double-dummy, parallel group study to compare the efficacy and safety of intravenous ondansetron 8mg plus intravenous dexamethasone 20mg with oral ondansetron 24mg od plus oral dexamethasone 12mg od in the control of acute emesis and nausea induced by cisplatin chemotherapy
S3AC01 III A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective orthopaedic surgery.
S3AM01 III A Randomised, Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR38032) Administered as Either a Single IV Dose or a Continuous Infusion Over 24 hours In Acute Cisplatin-induced Emesis
S3AM06 III A randomised double-blind multicentre study to compare the clinical efficacy and safety of ondansetron (GR38032) and prochlorperazine in the prophylaxis of nausea and vomiting caused by fractionated radiotherapy
S3AP31 III To Compare the Efficacy and Safety of Ondansetron with Dexamethasone in the Prophylaxis of Nausea and Vomiting Induced by Non-Platinum-Containing Cancer Chemotherapy Regimens
S3AP37 III A Multicentre Double-Blind Crossover Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-Containing Cancer Chemotherapy Regimens
S3AT03 III A Randomised Double-Blind Multicentre Study to Compare the Clinical Efficacy and Safety of Ondansetron (GR38032F) and Metoclopramide in the Prophylaxis of Single Fraction Radiotherapy-Induced Nausea and Vomiting
S3AT04 III A Multicentre Double-Blind Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Chemotherapy Emesis Induced by FAC/FEC Regimens
S3AT12 III A Multicentre Double-Blind Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Acute and Delayed Nausea and Vomiting Induced by Cisplatin-Containing Cancer Chemotherapy Regimens
S3AT14 III A Randomised Double-Blind Study to Compare the Efficacy and Safety of Oral GR38032F with Metoclopramide in the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy Regimen(s) Containing Epirubicin and Cyclophosphamide
S3AT15 III A Randomised Double-Blind Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy Regimens Containing Cyclophosphamide in Combination with Doxorubicin or Epirubicin
S3AT20 III Comparison of Ondansetron vs Ondansetron + Dexamethasone in the control of delayed emesis and nausea induced by Cisplatin.
S3AV01 III A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective abdominal surgery.
S3AV02 III A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing major gynaecological surgery.
S3AV05 III A randomized, double blind, parallel group study to compare the efficacy and tolerability of ondansetron vs metoclopramide in the prevention of post-operative nausea and vomiting in patients undergoing ophthalmic surgery
S3GT04 III A Double-Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of Intravenously Administered Ondansetron In The Prevention Of Post-Operative Nausea And Vomiting In Patients Having General Anaesthesia And Undergoing Major Gynaecological Surgery
S3GT05 III A double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of single doses of orally administered ondansetron in the prevention of post-operative nausea and vomiting in patients having general anaesthesia and undergoing major gynaecological surgery
S3GT07 III A Randomised, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Single Intravenous Bolus Dose of Ondansetron 4mg in the Prevention of Postoperative Nausea and Emesis in Patients Having General Anesthesia and Undergoing Day-case Surgery for Inguinal Hernia Repair, Varicose Veins and Arthroscopy
S3GT09 III A double-blind, placebo-controlled multicentre study of intravenous ondansetron in the prevention of post-operative emesis (retching and vomiting) in paediatric patients undergoing strabismus surgery
S3GT10 III A randomised, double-blind, placebo-controlled multicentre parallel-group study to compare the efficacy and safety of a single intravenous bolus dose of ondansetron, metoclopramide and placebo in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing gynaecological surgery.
TP552001 III A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.
TP552002 III A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.
ZOF S3A40320 III An Open-label, Multicenter, Study of the Safety and Antiemetic Effect of 0.15 mg/kg Intravenous Ondansetron Hydrochloride Administered for Three Doses to Pediatric Cancer Patients Aged 6 Months to 48 Months Who Are Receiving Moderately to Highly Emetogenic Chemotherapy
102245 II A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing With a New Chemical Entity (NCE) for Three Consecutive Days when Administered with a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for Postoperative Nausea and Vomiting Who Were Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated with an Increased Emetogenic Risk
102260 II A multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel group phase II study to evaluate the safety, efficacy, and pharmacokinetics of an oral New Chemical Entity (NCE) when administered with intravenous ondansetron hydrochloride for the prevention of post-operative nausea and vomiting (PONV) and post-discharge nausea and vomiting (PDNV) in female subjects with known risk factors for PONV who are undergoing surgical procedures associated with an increased emetogenic risk.
GM2006/00037/00 II A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of a New Chemical Entity When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy.
NKE20001 II A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Parallel Group Study of the Efficacy and Safety of a New Chemical Entity When Administered as Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy.
NKV10001 II An open label, repeat dose, randomized, three period crossover, parallel group study to investigate the potential pharmacokinetic interactions between two doses of a new chemical entity (NCE) and ondansetron (OND) and dexamethasone (DEX) when co-administered in healthy adult subjects.
RM2006/00520/00 II A phase II multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel group study of the safety and efficacy of a new chemical entity when administered orally in combination with ondansetron hydrochloride and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer subjects receiving moderately emetogenic chemotherapy.
S3A-150 II An evaluation of the pharmacokinetic properties of intravenous ondansetron in children receiving chemotherapy.
S3A-237 II Treatment of Postoperative Nausea and Vomiting: A Randomized Double-Blind Comparison of Intravenous Ondansetron and Placebo in Female Patients Undergoing Laparoscopic Procedures
S3A-240 II A Randomized, Double-Blind, Placebo-Controlled Evaluation of Efficacy and Pharmacokinetic Parameters of Oral Ondansetron in the Prevention of Nausea and Vomiting Associated With Fractionated Total Body Irradiation
S3A-241 II A Randomized, Double-Blind Comparison of Intravenous Ondansetron and Placebo in the Prevention of Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Procedures
S3A-242 II A Randomized, Double-Blind Comparison of Intravenous Ondansetron and Placebo in the Prevention of Postoperative Nausea and Vomiting in Female Patients Undergoing Inpatient Surgical Procedures
S3A-243 II Prevention of Postoperative Nausea and Vomiting: A Randomized, Double-blind Study of Intravenous Ondansetron in Female Patients Undergoing Laparoscopic Procedures
S3A-255 II A Double-Blind, Placebo-Controlled, Dose-Ranging Study of Intravenous Ondansetron in the Treatment of Opioid-Induced Emesis
S3A-284 II A Double-Blind Dose Comparison of Oral GR-C507/75 in the Prevention of Delayed Nausea and Vomiting Associated With Cisplatin
S3A-287 II An Open Label Evaluation of Three Different Doses of Oral GR-C507/75 In the Prevention of Nausea and Vomiting Associated with Non-Cisplatin Chemotherapy
S3A-290 II A Randomized, Double-Blind Comparison of Intravenous GR-C507/75 (Ondansetron) and Placebo in the Treatment of Postoperative Nausea and Vomiting
S3A-291 II A Double-Blind Evaluation of Oral GR-38032F in the Prevention of Delayed Nausea and Vomiting Associated With High-Dose Cisplatin
S3AM20 II An open non-comparative single centre study to assess the efficacy and safety of ondansetron in the prophylaxis of cancer chemotherapy-induced nausea and vomiting in children.
S3AP36 II A Multi-Centre Study to Assess the Clinical Efficacy and Safety of GR38032F in the Prophylaxis of Cisplatin-Induced Nausea and Vomiting
S3AT07 II A Randomised, Double-Blind, Placebo Controlled Study Of The Efficacy And Safely Of Ondansetron (GR38032F) in The Prophylaxis Of Nausea And Vomiting Induced By The Combination Of Cyclophosphamide, Doxorubicin And Prednisolone With Vincristine (CHOP), VP16 Or VM26
S3AT17 II A Randomised Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Ondansetron Given Orally 8mg Three Times A Day in the Prophylaxis of Nausea and Vomiting Induced by the Combination of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Women with Breast Cancer
S3GP09 II A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral 16MG BD Ondansetron (GR38032F) in Preventing Post-Operative Nausea and Vomiting in Patients Having General Anaesthesia and Undergoing Major Gynaecological Surgery
S3GT01 II A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Ondansetron in the Prevention of Post-Operative Nausea and Vomiting in Patients Having General Anaesthesia and Undergoing Major Gynaecological Surgery
S3GT02 II A Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Orally Administered Ondansetron 8mg TDS in the Prevention of Post-Operative Nausea and Vomiting in Patients Having General Anaesthesia and Undergoing Major Gynaecological Surgery
S3GT03 II A Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Orally Administered Ondansetron 16mg TDS In The Prevention Of Post-Operative Nausea And Vomiting In Patients Having General Anaesthesia And Undergoing Major Gynaecological Surgery.
C93-077 I A study to investigate the relative bioavailability of ondansetron syrup and Zofran tablets 4 mg
GHP:87:19 I A Study To Evaluate The Effect Of Repeat Oral Dosing Of GR38032F At 8 Mg BD, 1 Mg BD And 0.25 Mg BD On Cognitive Function In Healthy Volunteers.
GHP:87:21 I A Study To Evaluate The Effect Of GR38032F On Psychomotor Performance After Repeat Oral Dosing In Healthy Volunteers.
GHP:90:19 I The Interaction Of Ondansetron And Temazepam.
GPK/91/010 (Protocol No. K91-007) I To compare the bioavailabilities of the clinical trial and production formulations of ondansetron tablets (8 mg) for post-operative nausea and vomiting.
NKE10001 I An open-label, repeat-dose, randomized, three-period crossover, parallel-group study to investigate the potential pharmacokinetic interactions between two doses of a new chemical entity (NCE) and ondansetron (OND) and dexamethasone (DEX) when co-administered in healthy adult subjects.
NKV100787 I An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron when Administered in Healthy Adult Subjects
S3A-154 I An Open Label, Randomized Evaluation of the Pharmacokinetic Properties of Intraveneous and Oral Doses of GR 38032F in Healthy, Elderly Volunteers
S3A-155 I An evaluation of the effect of chemotherapy on the pharmacokinetics of oral ondansetron (GR38032F).
S3A-156 I An evaluation of the effects of food and antacid on the absorption of oral ondansetron (GR 38032F).
S3A-157 I An evaluation of the steady-state pharmacokinetics of ondansetron after 1, 4 and 8 mg oral doses
S3A-158 I Comparison of the pharmacokinetics of ondansetron (GR38032F) in patients with various degrees of hepatic insufficiency and in normal healthy subjects.
S3A161 I A randomized, double-blind, placebo-controlled study of the effects of two dose levels of intravenous ondansetron on respiratory depression induced by alfentanil in healthy male volunteers.
S3A-166 I An evaluation of the pharmacokinetic properties of a single intravenous dose of GR38032 in healthy, adult male volunteers
S3A-171 I An evaluation of the effect of dosage on the pharmacokinetics of intravenous ondansetron.
S3A172 I An ascending dose safety and pharmacokinetic evaluation of ondansetron administered as single intravenous bolus doses to healthy male volunteers.
S3A173 I A dose-proportionality study of ondansetron administered as a single intravenous dose to healthy male volunteers.
S3A174 I A dose-proportionality study of ondansetron administered as a single oral dose (tablet) to healthy male volunteers.
S3A176 I Evaluation of the Effects of Cytochrome P-450 Enzyme Inducers (Carbamazepine and Phenytoin) on Ondansetron Pharmacokinetics.
S3A179 I Pharmacokinetics of 16 mg ondansetron suppository, 8 mg zofran tablet, and 8 mg zofran injection in healthy adult male and female subjects.
S3A405 I An Open-Label Evaluation of Ondansetron Versus Ondansetron Plus Dexamethasone and Chlorpromazine in the Prevention of Nausea and Vomiting Associated with Multiple-Day Cisplatin Chemotherapy
S3AA1002 I A Bioequivalence Study Comparing Three 8-mg Zofran® Tablets to a Single 24-mg Ondansetron Tablet
S3AA1003 I Dose-Response Effects of Ondansetron vs. Placebo on Morphine-Induced Nausea, Gastric Dysrhythmias and Plasma Vasopressin
S3AP48 I A Pilot Study to Determine the Safety and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Cancer Chemotherapy Regimens Containing Cisplatin, Carboplatin or Doxorubicin in Combination with either Cyclophosphamide or Ifosfamide in Children
S3AP54 I The pharmacokinetics of oral ondansetron (GR38032F) in elderly patients receiving cytotoxic chemotherapy or radiotherapy.
S3GK01 I A Study to Determine the Pharmacokinetics of Orally Administered Ondansetron 16mg in Patients Having Surgery Under General Anaesthesia
S3GK02 I The Pharmacokinetics of Ondansetron Following a Single Intravenous Dose in Paediatric Patients Undergoing General Anaesthesia
UCP-95-053 I An Evaluation of Relative Bioavailability of Ondansetron From an 8mg Zydis® Formulation and an 8mg Zofran® Tablet
W91-016 I The Pharmacokinetics and Tolerability of Ondansetron 4mg Given as an Intramuscular Injection
WHP:87:12, WHP:88:12 I Radioisotope Study To Investigate The Metabolic Disposition Of GR38032 In Man
WHP:89:26 I A Study Of The Cardiovascular Effects Of Intravenous GR38032F 16 Mg In Healthy Volunteers